Summary
Eli Lilly and Company reported a significant decline in revenue and net income for the third quarter and the first nine months of 2014 compared to the prior year. This downturn was primarily driven by the loss of U.S. patent exclusivity for key drugs like Cymbalta and Evista, which led to immediate generic competition and a sharp drop in sales for these products. Despite the revenue challenges, Lilly has made strategic moves, including the announced acquisition of Novartis Animal Health (NAH) and collaborations on promising late-stage pipeline assets such as baricitinib and tanezumab. The company also saw growth in several key product areas and international markets, partially offsetting the declines. Investors should monitor the impact of ongoing patent challenges for Alimta and the development of new drug candidates as key drivers for future growth and potential risks.
Financial Highlights
51 data points| Revenue | $4.88B |
| Cost of Revenue | $1.27B |
| Gross Profit | $3.61B |
| R&D Expenses | $1.24B |
| SG&A Expenses | $1.67B |
| Operating Expenses | $2.92B |
| Interest Expense | $38.10M |
| Net Income | $500.60M |
| EPS (Basic) | $0.47 |
| EPS (Diluted) | $0.47 |
| Shares Outstanding (Basic) | 1.07B |
| Shares Outstanding (Diluted) | 1.07B |
Key Highlights
- 1Worldwide total revenue decreased by 16% for the third quarter and the first nine months of 2014 compared to the same periods in 2013, largely due to the loss of U.S. patent exclusivity for Cymbalta and Evista.
- 2Net income saw a substantial decrease of 58% for the third quarter and 50% for the first nine months of 2014, reflecting the revenue decline and increased expenses related to acquired in-process R&D and drug fee regulations.
- 3The company announced an agreement to acquire Novartis Animal Health (NAH) for approximately $5.4 billion, aiming to expand its animal health business.
- 4Several key products like Humalog, Cialis, Humulin, and Forteo showed positive sales growth in both the U.S. and international markets, partially offsetting revenue losses from patent expirations.
- 5Lilly has a robust late-stage pipeline with several new molecular entities (NMEs) in Phase III trials, including abemaciclib for breast and lung cancer, and baricitinib for rheumatoid arthritis.
- 6Significant litigation risks remain, particularly concerning patent challenges for Alimta and product liability claims related to Actos, Byetta, and Prozac, with potential material impacts on financial results.
- 7The company's financial condition remains solid with substantial cash and investments, although cash and cash equivalents decreased due to acquisitions, dividends, and share repurchases.